A Phase 3, Double Blind, Placebo Controlled, Randomized, Multicenter Clinical Trial to Demonstrate the Safety, Lot Consistency and Clinical Benefit of Recombinant Botulinum Vaccine A/B (rBV A/B)

Trial Profile

A Phase 3, Double Blind, Placebo Controlled, Randomized, Multicenter Clinical Trial to Demonstrate the Safety, Lot Consistency and Clinical Benefit of Recombinant Botulinum Vaccine A/B (rBV A/B)

Suspended
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs Botulism vaccine (Primary)
  • Indications Botulism
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 04 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Sep 2023.
    • 12 Nov 2013 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
    • 12 Nov 2013 Planned end date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top